source
- Lilly’s EloraTZP combo shows superior weight loss and glucose control, moves to Phase 3Eli Lilly reported that its experimental combination, EloraTZP, which pairs an amylin agonist with the approved obesity drug Zepbound, met all primary and secondary goals in a mid‑stage study of ad…
- Merck reports positive mid-stage results for Prometheus' tulisokibart in painful skin diseaseMerck presented new data from a mid-stage trial of tulisokibart, a drug acquired through its $10.8 billion purchase of Prometheus Biosciences. The trial evaluated multiple dose levels in patients…Endpoints · 22d agoPositive readoutPositive